The dataset was produced using fully resolved Large Eddy Simulation (LES) and multiharmonic rheological flow models in a realistic in silico phantom of the CoW. Researchers and biomedical engineers could utilize this dataset to fine-tune their CFD models and establish standard reference simulation(s) before carrying out further parametric studies. Having the dataset released under an open-access license encourages the community to further …
Blog
Three-year data bolster use of the BeGraft as a bridging stent in FEVAR
This advertorial is sponsored by Bentley. Stéphan Haulon (Hôpital Marie Lannelongue, GHPSJ, Paris, France) has extensive clinical experience using the BeGraft (Bentley, Hechingen, Germany) as a bridging stent in fenestrated endovascular aneurysm repair (FEVAR) procedures. He has conducted a pioneering study on the topic, with the latest published data pointing to excellent patency out to three […]
The post Three-year data bolster use of the BeGraft as a bridging stent in FEVAR appeared first on Vascular News.
ESMINT-EYMINT Survey Seeks to Assess Heparin Use in Stroke Thrombectomy
December 19, 2022—The European Society of Minimally Invasive Neurological Therapy (ESMINT) and EYMINT, its organization of young interventionists, are conducting a survey to obtain an overview of the use of any heparin in endovascular thrombectom…
RF Medical’s Mygen M-3004 and Myoblate Radiofrequency Ablation System Cleared by FDA
December 19, 2022—RF Medical Co., Ltd., a Korea-based manufacturer of thermal ablation systems, recently announced FDA clearance of the company’s Mygen M-3004 generator and Myoblate radiofrequency ablation system, which are now commercially…
Sonorous NV’s BossStent to Treat Symptomatic Cerebral Venous Diseases Used in First Patients in North America
December 16, 2022—Sonorous NV, Inc. announced that the company’s BossStent device, which is designed to treat patients with symptomatic cerebral venous diseases, was used in the first patients in North America.
The company will initiate …
Janssen’s Xarelto Studied for Secondary Prevention of VTE in Cancer Patients
December 15, 2022—The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated …
VentureMed’s FLEX First AV Registry Enrolls First Patient to Study Treatment of Arteriovenous Access Management
December 15, 2022—VentureMed Group, Inc. announced the commencement of enrollment in the FLEX First AV registry to evaluate arteriovenous (AV) access management with the company’s Flex Vessel Prep (VP) system. The Flex VP system has CE Mark…
Stryker’s Target Tetra Detachable Coil for Treating Small Aneurysms Cleared by FDA
December 15, 2022—Stryker announced FDA 510(k) clearance of the Target Tetra detachable coil, the latest addition to the company’s Target platform. The Target Tetra device, which is specifically designed to treat small aneurysms, combines a…
“Impressive” 12-month Flex vessel prep data presented at VEITHsymposium
VentureMed Group, a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced data presented at the VEITHsymposium, (15–19 November, New York, USA). Overall, the data presented demonstrated that Flex vessel prep used prior to balloon angioplasty improves 12-month […]
The post “Impressive” 12-month Flex vessel prep data presented at VEITHsymposium appeared first on Vascular News.
Corindus Rebranded as Siemens Healthineers Endovascular Robotics
December 14, 2022—Corindus, a Siemens Healthineers Company, announced it has been rebranded to Siemens Healthineers Endovascular Robotics, a dedicated business within the Advanced Therapies area of Siemens Healthineers. The aim of the Endovascula…